logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11766032 B1

PDFFull Text
Date of Patent:
Sep. 26, 2023

Filed:

Nov. 01, 2019

Genetically modified non-human animals expressing human epo

Applicants:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Yale University, New Haven, CT (US);

Institute for Research IN Biomedicine (Irb), Belinzona, CH;

Inventors:

Andrew J. Murphy, Croton-on-Hudson, NY (US);

Sean Stevens, San Francisco, CA (US);

Richard Flavell, Guilford, CT (US);

Markus Gabriel Manz, Bellinzona, CH;

Liang Shan, New Haven, CT (US);

Assignees:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Yale University, New Haven, CT (US);

Institute for Research in Biomedicine (IRB), Bellinzona, CH;

Attorneys:

Casey Donahoe

Brian E. Davy

Bozicevic, Field & Francis LLP

Primary Examiner:

Shin Lin Chen

Int. Cl.
CPC ...
A01K 67/00 (2006.01); A01K 67/027 (2006.01); C07H 21/04 (2006.01); C12N 9/14 (2006.01); C07K 14/54 (2006.01); C07K 14/475 (2006.01); C12Q 1/18 (2006.01); C07K 14/505 (2006.01); C12N 9/00 (2006.01); C07K 14/535 (2006.01); C07K 14/47 (2006.01); G01N 33/50 (2006.01); C07K 14/715 (2006.01); A61K 49/00 (2006.01); C07K 14/52 (2006.01);
U.S. Cl.
CPC ...
A01K 67/0271 (2013.01); A01K 67/0276 (2013.01); A01K 67/0278 (2013.01); A61K 49/0008 (2013.01); C07K 14/4703 (2013.01); C07K 14/475 (2013.01); C07K 14/505 (2013.01); C07K 14/524 (2013.01); C07K 14/535 (2013.01); C07K 14/5403 (2013.01); C07K 14/5437 (2013.01); C07K 14/7155 (2013.01); C12N 9/00 (2013.01); C12N 9/14 (2013.01); C12Q 1/18 (2013.01); G01N 33/5088 (2013.01); A01K 2207/12 (2013.01); A01K 2207/15 (2013.01); A01K 2217/05 (2013.01); A01K 2217/072 (2013.01); A01K 2217/075 (2013.01); A01K 2217/15 (2013.01); A01K 2227/105 (2013.01); A01K 2267/01 (2013.01); A01K 2267/0337 (2013.01); A01K 2267/0381 (2013.01); C12Y 301/03048 (2013.01);
Abstract

Genetically modified non-human animals expressing human EPO from the animal genome are provided. Also provided are methods for making non-human animals expressing human EPO from the non-human animal genome, and methods for using non-human animals expressing human EPO from the non-human animal genome. These animals and methods find many uses in the art, including, for example, in modeling human erythropoiesis and erythrocyte function; in modeling human pathogen infection of erythrocytes; in in vivo screens for agents that modulate erythropoiesis and/or erythrocyte function, e.g. in a healthy or a diseased state; in in vivo screens for agents that are toxic to erythrocytes or erythrocyte progenitors; in in vivo screens for agents that prevent against, mitigate, or reverse the toxic effects of toxic agents on erythrocytes or erythrocyte progenitors; in in vivo screens of erythrocytes or erythrocyte progenitors from an individual to predict the responsiveness of an individual to a disease therapy.

Find Patent Forward Citations

Loading…